escitalopram + tamoxifen

Escitalopram + tamoxifen is a combination of two small molecule drugs used together primarily in women with breast cancer who require both antidepressant therapy and anti-estrogen treatment. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that acts by increasing serotonin levels in the brain through inhibition of the serotonin transporter. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in breast tissue and is widely used for hormone receptor-positive breast cancer prevention and treatment. A key clinical consideration with this combination involves drug-drug interactions mediated by cytochrome P450 2D6 (CYP2D6). Tamoxifen requires metabolic activation via CYP2D6 to form its active metabolite endoxifen. Some SSRIs are strong inhibitors of CYP2D6 and can reduce endoxifen levels, potentially decreasing the efficacy of tamoxifen. However, escitalopram is considered a weak or minimal inhibitor of CYP2D6 compared to other SSRIs like paroxetine or fluoxetine[1][3][4][5][7]. Clinical studies have shown that switching from strong CYP2D6-inhibiting antidepressants to escitalopram increases endoxifen exposure without compromising depression management[3]. Thus, escitalopram is often preferred as an antidepressant for patients on tamoxifen therapy due to its lower risk for clinically significant interaction.

Brand names

Lexapro + NolvadexCipralex + NolvadexLexapro + tamoxifenCipralex + tamoxifen

Other names

escitalopram oxalate + tamoxifen citrate